约翰霍普金斯医学院的研究人员表示，他们在转基因小鼠的研究中发现了一个与 Aplp1 相关的潜在新生物靶点。Aplp1 是一种细胞表面蛋白，可促进导致帕金森病的 α-突触核蛋白的扩散。这项于 5 月 31 日发表在《Nature Communications》上的研究结果显示，Aplp1 如何与另一个细胞表面受体 Lag3 相互作用，在一个关键过程中发挥作用，该过程有助于将有害的 α-突触核蛋白运输到脑细胞中。这些蛋白质的聚集是帕金森病的特征。研究人员指出，特别值得注意的是，Lag3 已经是美国食品药品监督管理局 (FDA) 批准的一种联合癌症药物的目标，该药物利用抗体“教会”人体免疫系统去识别和摧毁什么。原始论文
A study by the University of the Basque Country (UPV/EHU) and Biobizkaia proposes using an available, simple, non-invasive tool to monitor this neurodegeneration Although there are still some aspects pending confirmation for its use in the clinical setting, and its resolution needs to be improved slightly, a study by the UPV/EHU and Biobizkaia has shown that a method routinely used to carry out ophthalmological tests can also be used to monitor the neurodegeneration that occurs in Parkinson’s patients. In the course of the research it was found that the neurodegeneration of the retina probably precedes cognitive impairment. Today, identifying Parkinson’s patients at risk of cognitive impairment poses a major challenge, yet this is necessary when it comes to providing more effective clinical treatments and stepping up clinical trials. In fact, Dr Ane Murueta-Goyena, in collaboration with Biobizkaia’s research staff, wanted…
